|
Mutation Information
|
Mutation Site
|
M552I |
|
Mutation Type
|
Amino acid level |
|
Gene/Protein/Region Type
|
P |
|
Combined Mutation
|
p.M552I+p.L528M |
|
Genotype/Subtype
|
D |
|
Relevant Drug
|
lamivudine (LAM) |
|
Country
|
Japan |
Literature Information
|
PubMed PMID
|
11181644
|
|
Published Year
|
2001 |
|
Journal
|
The Journal of clinical investigation |
|
Title
|
The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance. |
|
Author
|
Ono SK,Kato N,Shiratori Y,Kato J,Goto T,Schinazi RF,Carrilho FJ,Omata M |
|
Evidence
|
After receiving lamivudine for 3 years to treatChronic hepatitis B, 67-75% of patients develop B-domain L528M, C-domain M552I, or M552V mutations in the HBV polymerase that render hepatitis B virus (HBV) drug-resistant.
|
|
|
HBV Mutation Detail Information